End­points hon­ors 20 women su­per­charg­ing drug R&D; Omi­cron is a 'stress test' for the next pan­dem­ic; Roche and Genen­tech strike an AI pact with Re­cur­sion; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The bulk of this week’s re­port is brought to you by End­points ed­i­tors Nicole De­Feud­is and Max Gel­man, who are cov­er­ing for me as I take a few days off af­ter the big Women in Bio­phar­ma R&D event. We are re­al­ly proud of both the spe­cial re­port and the live pan­el, which fea­tured some great sto­ries from trail­blaz­ing lead­ers and in­sights on gen­der di­ver­si­ty in biotech. Do check them out be­low if you haven’t had a chance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.